Literature DB >> 20068154

A single nucleotide change in the mouse genome accelerates breast cancer progression.

Nina Seitzer1, Thomas Mayr, Sylvia Streit, Axel Ullrich.   

Abstract

In the growth factor receptor gene FGFR4 the presence of the common single nucleotide polymorphism Arg388 has been associated with progression of various types of cancer including breast cancer. However, a causative relationship is not readily assigned due to genetic heterogeneity in different patient cohorts. To address this issue, we compared the effects of this allele on malignant progression in the WAP-TGFalpha transgenic mouse model of breast cancer. A knock-in strain was generated to introduce an analogous Arg385 allele into the murine FGFR4 gene. Mouse embryonic fibroblasts derived from this strain displayed accelerated cell transformation, with transformed cells exhibiting greater motility and invasive behavior. In the in vivo context of TGFalpha-induced mammary carcinogenesis, tumor development and progression was significantly advanced in tumor mass, size, and onset of pulmonary metastases. Our findings definitively identify the FGFR4 Arg388 allele as a functional prognostic marker for breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068154     DOI: 10.1158/0008-5472.CAN-09-3239

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model.

Authors:  Gregory A Azzam; Amanda K Frank; Monica Hollstein; Maureen E Murphy
Journal:  Cell Cycle       Date:  2011-05-01       Impact factor: 4.534

Review 3.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

4.  STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.

Authors:  Daniel Kogan; Alexander Grabner; Christopher Yanucil; Christian Faul; Vijay Kumar Ulaganathan
Journal:  J Clin Invest       Date:  2018-04-03       Impact factor: 14.808

5.  Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Authors:  Alexander Grabner; Ansel P Amaral; Karla Schramm; Saurav Singh; Alexis Sloan; Christopher Yanucil; Jihe Li; Lina A Shehadeh; Joshua M Hare; Valentin David; Aline Martin; Alessia Fornoni; Giovana Seno Di Marco; Dominik Kentrup; Stefan Reuter; Anna B Mayer; Hermann Pavenstädt; Jörg Stypmann; Christian Kuhn; Susanne Hille; Norbert Frey; Maren Leifheit-Nestler; Beatrice Richter; Dieter Haffner; Reimar Abraham; Johannes Bange; Bianca Sperl; Axel Ullrich; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

Review 6.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

7.  Mouse models for the p53 R72P polymorphism mimic human phenotypes.

Authors:  Feng Zhu; Martijn E T Dollé; Thomas R Berton; Raoul V Kuiper; Carrie Capps; Alexsandra Espejo; Mark J McArthur; Mark T Bedford; Harry van Steeg; Annemieke de Vries; David G Johnson
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

8.  Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function.

Authors:  Adam C Pond; Xue Bin; Torey Batts; Kevin Roarty; Susan Hilsenbeck; Jeffrey M Rosen
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

9.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.

Authors:  Saurav Singh; Alexander Grabner; Christopher Yanucil; Karla Schramm; Brian Czaya; Stefanie Krick; Mark J Czaja; Rene Bartz; Reimar Abraham; Giovana S Di Marco; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Kidney Int       Date:  2016-07-22       Impact factor: 10.612

10.  Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study.

Authors:  Nao Souma; Tamara Isakova; David Lipiszko; Ralph L Sacco; Mitchell S V Elkind; Janet T DeRosa; Shonni J Silverberg; Armando J Mendez; Chuanhui Dong; Clinton B Wright; Myles Wolf
Journal:  J Clin Endocrinol Metab       Date:  2016-08-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.